List view / Grid view
4 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Øystein Soug is the former CFO of Algeta, a Norwegian oncology biotech company which was sold to Bayer for USD 2.9 billion in 2014...
12 July 2016 | By Victoria White, Digital Content Producer
In a deal worth up to $528 million, Bayer and X-Chem are to collaborate to discovery therapies across multiple therapeutic areas and target classes...
8 June 2016 | By Dr Alexander Moscho, Bayer UK & Ireland CEO
In this opinion piece, Dr Alexander Moscho, Bayer UK & Ireland CEO, says a vote to leave the EU will deter investment and make it harder for patients to access new medicines...
8 March 2016 | By Victoria White
Scientists at the Universities of Dundee and Cape Town are teaming up with Bayer to develop critically needed new treatments for tuberculosis...
21 December 2015 | By Victoria White
Bayer and CRISPR Therapeutics are to form the joint venture to discover, develop and commercialise new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease...
23 April 2015 | By Victoria White
Bayer and UKE are the main coordinators of a new international consortium, CANCER-ID, to develop novel blood-based biomarker technologies in cancer...
13 April 2015 | By Victoria White
Bayer HealthCare has expanded its collaboration with the Broad Institute to include cardiovascular genomics and drug discovery...
Preclinical drug target validation has the aim to increase confidence in a particular drug target. The process proves the initial hypothesis that a particular molecular target is key or even causative for pathogenic or symptomatic mechanisms in a disease. Several success factors seem to be of particular importance for the…
12 March 2014 | By Amgen
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...
